ClinicalTrials.Veeva

Menu

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

C

Curegenix

Status and phase

Unknown
Phase 1

Conditions

Esophageal Carcinoma
Colorectal Adenocarcinoma
Gastrointestinal Cancer
Pancreatic Adenocarcinoma
Hepatocellular Carcinoma
Bile Duct Carcinoma
Gastric Adenocarcinoma

Treatments

Drug: CGX1321

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT03507998
CGX1321-102

Details and patient eligibility

About

This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.

Full description

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment.

Once the dose is identified in the Dose Escalation Phase, the Dose Expansion Phase will start. The purpose of the Dose Expansion Phase is to continue to examine the safety and confirm the final Phase 2 dose of CGX1321 when administered to subjects with advanced GI tumors who meet the entry criteria.

Enrollment

39 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically-diagnosed advanced Gl tumors, such as colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, bile duct carcinoma, hepatocellular carcinoma, esophageal carcinoma that have relapsed or are refractory to or are not considered medically suitable to receive standard of care treatment
  • Eastern Cooperative Oncology Group (ECOG) score of 0 - 1
  • Minimum estimated life expectancy of 3 months
  • Adequate organ function
  • Recovery from prior treatment-related toxicities
  • Ability to swallow capsules
  • Willingness for subjects of reproductive potential to use adequate methods of contraception during and for 3 months after study treatment

Exclusion criteria

  • Prior exposure to a WNT inhibitor
  • Received previous therapy for malignancy within 21 days
  • Major surgery within 4 weeks of first dose of study drug
  • Radiotherapy within 2 weeks of first dose of study drug
  • Significant GI or variceal bleeding or subdural hematoma within 3 months of treatment start
  • Uncontrolled central nervous system metastases or leptomeningeal metastases
  • Requirement for immunosuppressive agents (must be off for at least 7 days)
  • Currently receiving medications that are known CYP3A4/5 inhibitors. Patients currently receiving medications of known inducers of CYP3A4/5 or substrates of CYP2C8/9 and CYP1A2 may be excluded.
  • Bone abnormalities
  • Hypercalcemia
  • Cardiac abnormalities
  • Known human immunodeficiency virus positive, or active hepatitis A, B or C
  • History of additional prior malignancy with the exception of surgically cured carcinomas such as skin, prostate, bladder, thyroid, cervix or other carcinomas in situ
  • Active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start
  • Pregnancy or lactation

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

39 participants in 1 patient group

CGX1321 Dosing
Experimental group
Description:
Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned. Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321
Treatment:
Drug: CGX1321

Trial contacts and locations

2

Loading...

Central trial contact

Peter Ding

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems